Chase Therapies Inc (EIN 471485721) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2022

Legal Domicile

Phone

3863107879

Tax Period

2024-01-01 to 2024-12-31

Chase Therapies Inc, founded in 2022, is a small nonprofit in the Health Care sector that reported $567K in total revenue in fiscal year 2024. Revenue surged 68% from the prior year, signaling strong growth momentum.

Mission

The mission of Chase Therapies Inc is to provide therapeutic support services to children with Autism Spectrum primarily those attending our sister agency The Chase Academy a non-profit private school for children with autism with the goal of supporting TCAs goal of maximizing independence towards assimilation into mainstream society in adulthood.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $566,706

Investment Income $0

Other Revenue $0

TOTAL REVENUE $566,706

Expense Breakdown

Grants Paid $0

Salaries & Benefits $536,257

Fundraising Expenses $0

Program Expenses $461,144

Other Expenses $37,662

TOTAL EXPENSES $573,919

Year-over-Year Comparison

	2024	2023	Change
Revenue	$566,706	$337,281	+0.7%
Expenses	$573,919	$356,866	+0.6%
Net Income	$-7,213	$-19,585	-0.6%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

N/A

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

$211,916

Key Employees

$61,684

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Miriam E Lundell	Executive Director	20.00	Director	$31,254	$0	$108,290
Amy K Filson	Programming Director	25.00	Director	$38,109	$0	$103,626
Natasha Boges	Clinical Director BCBA	40.00	Highest	$31,972	$0	$31,972
Christina	Tucker	40.00	Key Emp Highest	$61,684	$0	$61,684

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$566,706	$573,919	$1,791	$-7,213
2023	No data	No data	No data	No data

Chase Therapies Inc